Although clinical trials are been conducted targeting G12C mutant Kras (AMG 510 (NCT03600883) and MRTX849 (NCT03785249)) along with active research on siRNA delivery 47, KRAS mutation positive NSCLC remains the most difficult subtype of lung cancers to treat. This evidence concerns the gene KRAS and lung cancer.